Citations (121)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Aditi Saha, Khushali Jhaveri, Humaira Sarfraz & Julio C Chavez. (2023) Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. Expert Opinion on Biological Therapy 23:9, pages 869-876.
Read now
Read now
Varada Date & Sujit Nair. (2021) Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opinion on Biological Therapy 21:2, pages 145-160.
Read now
Read now
Jianfeng Zhao, Lijuan Lin, Yihua Luo, Qinghe Cai, Xiaojie Jiang, Changxi Liao & Huimin Wei. (2021) Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells. Bioengineered 12:1, pages 3674-3683.
Read now
Read now
Xinnuo Lei, Xiong Cai & Yi Yang. (2020) Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines. Expert Review of Vaccines 19:3, pages 235-246.
Read now
Read now
Haiyuan Yu, Jun Pan, Zhicheng Guo, Chunhua Yang & Lijun Mao. (2019) CART cell therapy for prostate cancer: status and promise. OncoTargets and Therapy 12, pages 391-395.
Read now
Read now
Liang Wang, Tianmin Xu & Manhua Cui. (2018) Are ovarian cancer stem cells the target for innovative immunotherapy?. OncoTargets and Therapy 11, pages 2615-2626.
Read now
Read now
Yao Wang, Meixia Chen, Zhiqiang Wu, Chuan Tong, Hanren Dai, Yelei Guo, Yang Liu, Jianhua Huang, Haiyan Lv, Can Luo, Kai-chao Feng, Qing-ming Yang, Xiao-lei Li & Weidong Han. (2018) CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. OncoImmunology 7:7.
Read now
Read now
Laurent Boissel, Monica Betancur, Weiquan Lu, Daniela Krause, Richard Van Etten, Winfried Wels & Hans Klingemann. (2013) Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. OncoImmunology 2:10.
Read now
Read now
Xiao-Jun Xu, Hai-Zhao Zhao & Yong-Min Tang. (2013) Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leukemia & Lymphoma 54:2, pages 255-260.
Read now
Read now
Panayotis Kaloyannidis, Ann M Leen & Anastasia Papadopoulou. (2012) T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation. Expert Review of Hematology 5:5, pages 471-473.
Read now
Read now
Articles from other publishers (110)
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko, Alexandr Migas, Simon Dubovik & Natalya Konoplya. (2023) CAR-T Cell Therapy for Classical Hodgkin Lymphoma. HemaSphere 7:12, pages e971.
Crossref
Crossref
Abhinava K. Mishra, Ashna Gupta, Gunjan Dagar, Dayasagar Das, Abhijit Chakraborty, Shabirul Haque, Chandra Prakash Prasad, Archana Singh, Ajaz A. Bhat, Muzafar A. Macha, Moez Benali, Kamal S. Saini, Rebecca Ann Previs, Deepak Saini, Dwaipayan Saha, Preyangsee Dutta, Aseem Rai Bhatnagar, Mrinalini Darswal, Abhishek Shankar & Mayank Singh. (2023) CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines 11:11, pages 1721.
Crossref
Crossref
Maryam Zare Moghaddam, Mohammad Javad Mousavi & Somayeh Ghotloo. (2023) Cell‐based therapies for the treatment of rheumatoid arthritis. Immunity, Inflammation and Disease 11:11.
Crossref
Crossref
Gede Kambayana & Sandra Surya Rini. (2023) Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as
the Future of Systemic Lupus Erythematosus Treatment. Current Rheumatology Reviews 19:3, pages 260-269.
Crossref
Crossref
Yong Xia, Hui Xue, Jing Li, Yanyan Yu, Wei Huang, Chuchu Zhou, Tingting Shi, Yanxia Cheng, Caihong Zhang, Shuang Liu, Zongchang Song, Sha Xu & Jinxing Lou. (2023) A nomogram prediction of citrate reaction during mononuclear cell collection in solid tumor patients. Journal of Clinical Apheresis 38:4, pages 422-426.
Crossref
Crossref
Amanda M. Buck, Tyler-Marie Deveau, Timothy J. Henrich & Amelia N. Deitchman. (2023) Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies. Viruses 15:5, pages 1126.
Crossref
Crossref
Nasim Adabi, Safoora Pordel, Mohammad Ali Rezaee, Fatemeh Sadat Shobeiri & Saeideh Sadat Shobeiri. (2023) Application of CAR‐T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment. The Journal of Gene Medicine 25:5.
Crossref
Crossref
Anil Kumar, Vipasha Gautam, Arushi Sandhu, Kajal Rawat, Antika Sharma & Lekha Saha. (2023) Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World Journal of Gastrointestinal Surgery 15:4, pages 495-519.
Crossref
Crossref
Shanglin Yang. (2023) CAR-T cells therapy: a potential new strategy against prostate cancer. Highlights in Science, Engineering and Technology 36, pages 1468-1473.
Crossref
Crossref
Yuting Lu, Tangye Zeng, Huamiao Zhang, Yang Li, Xiaoling Zhu, Huiping Liu, Beibei Sun, Chaoran Ji, Ting Li, Leyi Huang, Kesong Peng, Zhe Tang & Longguang Tang. (2023) Nano-immunotherapy for lung cancer. Nano TransMed 2:1, pages e9130018.
Crossref
Crossref
Banafshe Abadi & Nima Rezaei. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
25
.
Mark C. Glassy. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
20
.
Jian Yang, Jinwen Zhang, Jia Wei, Guangjie Wu, Jianxin Song, Dong Liu & Yan He. (2022) Prolonged Duration of Lymphocyte Deficiency, High-grade CRS, and Ventilation Are Linked to Fungal Breakthrough in Patients with Hematologic Malignancies 60 Days after CAR-T Infusion: a Single Center Case-Control Study. Journal of Infection and Public Health.
Crossref
Crossref
Xavier Ramos‑Cardona, Weichuan Luo & Sulma Mohammed. (2022) Advances and challenges of CAR T therapy and suitability of animal models (Review). Molecular and Clinical Oncology 17:3.
Crossref
Crossref
Maarten Slebe, Johanna E.E. Pouw, Sayed M.S. Hashemi, C. Willemien Menke-van der Houven van Oordt, Maqsood M. Yaqub & Idris Bahce. (2022) Current state and upcoming opportunities for immunoPET biomarkers in lung cancer. Lung Cancer 169, pages 84-93.
Crossref
Crossref
Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Tanveer Ahmad, Saqer S. Alotaibi, Mohammad M. Al-Sanea & Hisham Althobaiti. (2022) Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Elodie Bôle-Richard, Naveen Pemmaraju, Blandine Caël, Etienne Daguindau & Andrew A. Lane. (2022) CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers 14:9, pages 2287.
Crossref
Crossref
Yangyi Zhang, Bethany K. Campbell, Stanley S. Stylli, Niall M. Corcoran & Christopher M. Hovens. (2022) The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro 2:2, pages 74-92.
Crossref
Crossref
Yasushi Kimura, Mario Ghosn, Waseem Cheema, Prasad S. Adusumilli, Stephen B. Solomon & Govindarajan Srimathveeralli. (2022) Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. Molecular Therapy - Oncolytics 24, pages 194-204.
Crossref
Crossref
Ali Zarezadeh Mehrabadi, Reza Ranjbar, Mahdieh Farzanehpour, Alireza Shahriary, Ruhollah Dorostkar, Mohammad Ali Hamidinejad & Hadi Esmaeili Gouvarchin Ghaleh. (2022) Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomedicine & Pharmacotherapy 146, pages 112512.
Crossref
Crossref
桃 李. (2022) Progress of CAR-T Therapy in Gastric Cancer. Advances in Clinical Medicine 12:04, pages 2500-2509.
Crossref
Crossref
Sanjay Rathod. 2022. CAR T cells: development, characterization and applications. CAR T cells: development, characterization and applications
71
80
.
Weizhen Li, Yang Zhou, Zhongen Wu, Yaoping Shi, Enming Tian, Yingqi Zhu, Tao Wang, Wei Dou, Xiangjing Meng, Ming Chen, Bo Zhai & Di Zhu. (2021) Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy. Frontiers in Pharmacology 12.
Crossref
Crossref
Laeth L. George, Saarang R. Deshpande, Matthew J. Cortese, Ellen K. Kendall, Asmi Chattaraj, Zunairah Shah, Jianjun Zhao & Faiz Anwer. (2021) Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clinical Lymphoma Myeloma and Leukemia 21:11, pages 741-751.
Crossref
Crossref
Megha Suri, Nitin Soni, Nkiruka Okpaleke, Shikha Yadav, Suchitra Shah, Zafar Iqbal, Mohammed G Alharbi, Harjeevan S Kalra & Pousette Hamid. (2021) A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review. Cureus.
Crossref
Crossref
Yanjun Zheng, Kutty Selva Nandakumar & Kui Cheng. (2021) Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. Journal of Medicinal Chemistry 64:14, pages 9577-9591.
Crossref
Crossref
Anuradha Bishnoi, Dipankar De, Sanjeev Handa & Rahul Mahajan. (2021) Biologics in autoimmune bullous diseases: Current scenario. Indian Journal of Dermatology, Venereology and Leprology 87, pages 611-620.
Crossref
Crossref
Maryam Akhoundi, Mahsa Mohammadi, Seyedeh Saeideh Sahraei, Mohsen Sheykhhasan & Nashmin Fayazi. (2021) CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology 44:3, pages 495-523.
Crossref
Crossref
Peng LüSonglin QiuYe PanFeng YuKeping Chen. (2021) Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers. Cancer Biotherapy and Radiopharmaceuticals 36:4, pages 307-315.
Crossref
Crossref
Etienne Leveille & Nathalie A. Johnson. (2021) Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. Cancers 13:9, pages 2167.
Crossref
Crossref
Yan Dong, Zhuo Wan, Xiaotong Gao, Guodong Yang & Li Liu. (2021) Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies. Frontiers in Immunology 12.
Crossref
Crossref
Ke-Tao Jin, Bo Chen, Yu-Yao Liu, H uan-Rong Lan & Jie-Ping Yan. (2021) Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell International 21:1.
Crossref
Crossref
Risa L. Wong & Evan Y. Yu. (2021) Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. Current Treatment Options in Oncology 22:2.
Crossref
Crossref
Kewal K. Jain. (2021) Personalized Immuno-Oncology. Medical Principles and Practice 30:1, pages 1-16.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2021. Textbook of Personalized Medicine. Textbook of Personalized Medicine
479
508
.
E. V Abakushina. (2020) Immunotherapeutic approaches in the treatment of COVID-19. Genes & Cells 15:4, pages 19-26.
Crossref
Crossref
Muhammad Sadeqi Nezhad, Alexander Seifalian, Nader Bagheri, Sajad Yaghoubi, Mohammad Hossein Karimi & Meghdad Adbollahpour-Alitappeh. (2020) Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?. Frontiers in Immunology 11.
Crossref
Crossref
Gordon Minru Xiong, Kailash Venkatraman & Subbu Venkatraman. (2020) The magic bullet as cancer therapeutic—has nanotechnology failed to find its mark?. Progress in Biomedical Engineering 2:4, pages 042004.
Crossref
Crossref
Nor Adzimah Johdi & Nur Fazilah Sukor. (2020) Colorectal Cancer Immunotherapy: Options and Strategies. Frontiers in Immunology 11.
Crossref
Crossref
Ali Zamat, Linshan Zhu & Yingxiao Wang. (2019) Engineering Molecular Machines for the Control of Cellular Functions for Diagnostics and Therapeutics. Advanced Functional Materials 30:37, pages 1904345.
Crossref
Crossref
Laura Sanz-Ortega, José Manuel Rojas & Domingo F. Barber. (2020) Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting. Pharmaceutics 12:9, pages 812.
Crossref
Crossref
Laxman Devkota, Zbigniew Starosolski, Charlotte H. RivasIgor StupinAnanth AnnapragadaKetan B. Ghaghada & Robin Parihar. (2020) Detection of response to tumor microenvironment–targeted cellular immunotherapy using nano-radiomics. Science Advances 6:28.
Crossref
Crossref
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn, Matthew J. Frigault, Elizabeth K. O’Donnell, Caron A. Jacobson, Shveta S. Motwani, Samir M. Parikh, Gary C. Curhan, Kerry L. Reynolds, David E. Leaf & Meghan E. Sise. (2020) Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. American Journal of Kidney Diseases 76:1, pages 63-71.
Crossref
Crossref
Jinxin Qi, Chengchao Ding, Xian Jiang & Yong Gao. (2020) Advances in Developing CAR T-Cell Therapy for HIV Cure. Frontiers in Immunology 11.
Crossref
Crossref
Bo Long, Long Qin, Boya Zhang, Qiong Li, Long Wang, Xiangyan Jiang, Huili Ye, Genyuan Zhang, Zeyuan Yu & Zuoyi Jiao. (2020) CAR T‑cell therapy for gastric cancer: Potential and perspective (Review). International Journal of Oncology.
Crossref
Crossref
Samuel G. Katz & Peter M. Rabinovich. 2020. Cell Reprogramming for Immunotherapy. Cell Reprogramming for Immunotherapy
3
44
.
Zuzanna Rzepka, Marta Knapik & Dorota Wrześniok. (2019) Strategies of current cancer immunotherapy. Postępy Higieny i Medycyny Doświadczalnej 73, pages 898-908.
Crossref
Crossref
Britten, Ragusa, Tosi & Kamel. (2019) MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?. Cells 8:11, pages 1341.
Crossref
Crossref
Dan Li, Xue Li, Wei-Lin Zhou, Yong Huang, Xiao Liang, Lin Jiang, Xiao Yang, Jie Sun, Zonghai Li, Wei-Dong Han & Wei Wang. (2019) Genetically engineered T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Xu Zhang, Di Sun & Gui-Chun Jiang. (2019)
Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports
†
. Frontiers of Nursing 6:2, pages 87-95.
Crossref
Crossref
Parnian Jabbari, Sara Hanaei & Nima Rezaei. (2019) State of the art in immunotherapy of neuroblastoma. Immunotherapy 11:9, pages 831-850.
Crossref
Crossref
Otto L.D. Cerqueira, Gissele Rolemberg Oliveira Silva, Igor de Luna Vieira, Marlous Vinícius Gomes Lana, Nadine Gimenez, Otavio Augusto Rodrigues, Paulo Roberto Del Valle, Samir Andrade Mendonça & Bryan E. Strauss. 2019. In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders. In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders.
Carter M. Suryadevara, Rupen Desai, S. Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, David J. Snyder, James E. HerndonIIII, Patrick Healy, Elizabeth A. Reap, Gary E. Archer, Peter E. Fecci, John H. Sampson & Luis Sanchez-Perez. (2019) Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clinical Cancer Research 25:1, pages 358-368.
Crossref
Crossref
Nicholas Tokarew, Justyna Ogonek, Stefan Endres, Michael von Bergwelt-Baildon & Sebastian Kobold. (2018) Teaching an old dog new tricks: next-generation CAR T cells. British Journal of Cancer 120:1, pages 26-37.
Crossref
Crossref
Yiyin Zhang, Chao Yang, He Cheng, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kun Fan, Guopei Luo, Kaizhou Jin, Zhengshi Wang, Chen Liu & Xianjun Yu. (2018) Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Kewal K. Jain. (2018) A Critical Overview of Targeted Therapies for Glioblastoma. Frontiers in Oncology 8.
Crossref
Crossref
Ayguen Sahin, Carlos Sanchez, Szofia Bullain, Peter Waterman, Ralph Weissleder & Bob S. Carter. (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLOS ONE 13:7, pages e0199414.
Crossref
Crossref
Paolo StratiShabnum PatelLoretta NastoupilMichelle A. FanaleCatherine M. BollardAdam Y. LinLeo I. Gordon. (2018) Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book:38, pages 592-603.
Crossref
Crossref
Qiang Sun, Shixin Zhou, Jingjing Zhao, Changwen Deng, Ruidi Teng, Yiding Zhao, Jiajia Chen, Jiebin Dong, Ming Yin, Yun Bai, Hongkui Deng & Jinhua Wen. (2018) Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer. Oncotarget 9:17, pages 13694-13705.
Crossref
Crossref
Yingjun Xie, Yien Xiang, Jiyao Sheng, Dan Zhang, Xiaoxiao Yao, Yongsheng Yang & Xuewen Zhang. (2018) Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. Journal of Immunology Research 2018, pages 1-8.
Crossref
Crossref
Jonathan Fisher & John Anderson. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
161
174
.
Long Zheng, Peisheng Hu, Brandon Wolfe, Caryn Gonsalves, Luqing Ren, Leslie Khawli, Harvey Kaslow & Alan Epstein. (2017) Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. International Journal of Molecular Sciences 18:12, pages 2773.
Crossref
Crossref
Cheng Zhang, Jun Liu, Jiang F. Zhong & Xi Zhang. (2017) Engineering CAR-T cells. Biomarker Research 5:1.
Crossref
Crossref
Rusheni Munisvaradass, Suresh Kumar, Chandramohan Govindasamy, Khalid Alnumair & Pooi Mok. (2017) Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells. International Journal of Molecular Sciences 18:9, pages 1797.
Crossref
Crossref
Sara Caratelli, Tommaso Sconocchia, Roberto Arriga, Andrea Coppola, Giulia Lanzilli, Davide Lauro, Adriano Venditti, Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo, Soldano Ferrone & Giuseppe Sconocchia. (2017) FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Frontiers in Immunology 8.
Crossref
Crossref
Keyu Li, Yaliang Lan, Jiabei Wang & Lianxin Liu. (2017) Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles. Tumor Biology 39:3, pages 101042831769222.
Crossref
Crossref
Johan Garssen & Juandy Jo. (2017) Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible?. AIMS Allergy and Immunology 1:1, pages 43-49.
Crossref
Crossref
Qing Ma, Haven R. Garber, Sijie Lu, Hong He, Eran Tallis, Xiaoling Ding, Anna Sergeeva, Michael S. Wood, Gianpietro Dotti, Barbara Salvado, Kathryn Ruisaard, Karen Clise-Dwyer, Lisa St John, Katayoun Rezvani, Gheath Alatrash, Elizabeth J. Shpall & Jeffrey J. Molldrem. (2016) A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy 18:8, pages 985-994.
Crossref
Crossref
Verena Labenski, Julia D. Suerth, Elke Barczak, Dirk Heckl, Camille Levy, Ornellie Bernadin, Emmanuelle Charpentier, David A. Williams, Boris Fehse, Els Verhoeyen & Axel Schambach. (2016) Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes. Biomaterials 97, pages 97-109.
Crossref
Crossref
Carlos A. Ramos, Barbara Savoldo, Vicky Torrano, Brandon Ballard, Huimin Zhang, Olga Dakhova, Enli Liu, George Carrum, Rammurti T. Kamble, Adrian P. Gee, Zhuyong Mei, Meng-Fen Wu, Hao Liu, Bambi Grilley, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop & Gianpietro Dotti. (2016) Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. Journal of Clinical Investigation 126:7, pages 2588-2596.
Crossref
Crossref
Binh Thanh Vu, Dat Tan Le & Phuc Van Pham. (2016) Synergistic effect of chimeric antigen receptors and cytokineinduced killer cells: An innovative combination for cancer therapy. Biomedical Research and Therapy 3:6.
Crossref
Crossref
Timothy T. Spear, Kaoru Nagato & Michael I. Nishimura. (2016) Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunology, Immunotherapy 65:6, pages 631-649.
Crossref
Crossref
Bo-Ra Na, Min-Sung Kwon, Myoung-Won Chae, Hye-Ran Kim, Chang-Hyun Kim, Chang-Duk Jun & Zee-Yong Park. (2016) Transgelin-2 in B-Cells Controls T-Cell Activation by Stabilizing T Cell - B Cell Conjugates. PLOS ONE 11:5, pages e0156429.
Crossref
Crossref
Xi-zhi J Guo, Pradyot Dash, Matthew Calverley, Suzanne Tomchuck, Mari H Dallas & Paul G Thomas. (2016) Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis. Molecular Therapy - Methods & Clinical Development 3, pages 15054.
Crossref
Crossref
Katja Fiedler, Sandra Lazzaro, Johannes Lutz, Susanne Rauch & Regina Heidenreich. 2016. Current Strategies in Cancer Gene Therapy. Current Strategies in Cancer Gene Therapy
61
85
.
Joseph M. Cantor. 2016. Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
127
161
.
Claudia Geldres, Barbara Savoldo & Gianpietro Dotti. 2016. Tumor Immunology. Tumor Immunology
75
86
.
Yun Bai, Shifeng Kan, Shixin Zhou, Yuting Wang, Jun Xu, John P Cooke, Jinhua Wen & Hongkui Deng. (2015) Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. Cell Discovery 1:1.
Crossref
Crossref
Francesco Perri, Giuseppina Della Vittoria Scarpati, Mario Giuliano, Carmine D’Aniello, Antonio Gnoni, Carla Cavaliere, Antonella Licchetta & Salvatore Pisconti. (2015) Epstein–Barr virus infection and nasopharyngeal carcinoma. Anti-Cancer Drugs 26:10, pages 1017-1025.
Crossref
Crossref
Q Zhao, M Ahmed, D V Tassev, A Hasan, T-Y Kuo, H-F Guo, R J O'Reilly & N-K V Cheung. (2015) Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia 29:11, pages 2238-2247.
Crossref
Crossref
Milena Kalaitsidou, Gray Kueberuwa, Antje Schütt & David Edward Gilham. (2015) CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy 7:5, pages 487-497.
Crossref
Crossref
Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan & Wei Peng Yong. (2015) Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research 2015, pages 1-14.
Crossref
Crossref
Jessica Chacon, Krit Ritthipichai, Geok Sim, Michiko Harao, Jie Qing Chen, Caitlin Creasy, Chantale Bernatchez, Patrick Hwu & Laszlo Radvanyi. 2015. Developments in T Cell Based Cancer Immunotherapies. Developments in T Cell Based Cancer Immunotherapies
151
181
.
Tristen S. ParkDaniel Abate-DagaLing ZhangZhili ZhengRichard A. Morgan. (2014) Gamma-Retroviral Vector Design for the Co-Expression of Artificial microRNAs and Therapeutic Proteins. Nucleic Acid Therapeutics 24:5, pages 356-363.
Crossref
Crossref
Géraldine Lescaille, Juliette Rochefort, Rodney Macedo, Aline Le Moignic, Claude Baillou, Véronique Mateo, Chloé Bertolus & François M. Lemoine. (2014)
Immunité et cancers des voies aéro-digestives supérieures 2
e
partie. Immunothérapies des cancers des VADS
. Médecine Buccale Chirurgie Buccale 20:4, pages 245-252.
Crossref
Crossref
Usanarat Anurathapan, Ann M. Leen, Malcolm K. Brenner & Juan F. Vera. (2014) Engineered T cells for cancer treatment. Cytotherapy 16:6, pages 713-733.
Crossref
Crossref
Meaghan L Khan, Thorvardur R Halfdanarson & Mitesh J Borad. (2014) Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future Oncology 10:7, pages 1255-1275.
Crossref
Crossref
Gianpietro Dotti, Stephen Gottschalk, Barbara Savoldo & Malcolm K. Brenner. (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological Reviews 257:1, pages 107-126.
Crossref
Crossref
Stefan F. Martin, Sonja S. Schmucker & Anne Richter. 2014. T Lymphocytes as Tools in Diagnostics and Immunotoxicology. T Lymphocytes as Tools in Diagnostics and Immunotoxicology
73
88
.
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology
347
370
.
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology
509
547
.
Camilo Ayala-Breton, Stephen J. Russell & Kah-Whye Peng. 2014. Multiple Myeloma. Multiple Myeloma
141
158
.
Malcolm K Brenner. (2013) CAR T Cells for Acute Myeloid Leukemia: The LeY of the Land. Molecular Therapy 21:11, pages 1983-1984.
Crossref
Crossref
Hans G. Klingemann. (2013) Cellular therapy of cancer with natural killer cells—where do we stand?. Cytotherapy 15:10, pages 1185-1194.
Crossref
Crossref
Barbara Savoldo & Gianpietro Dotti. (2013) Chimeric antigen receptors (CARs) from bench-to-bedside. Immunology Letters 155:1-2, pages 40-42.
Crossref
Crossref
Michael H. Kershaw, Jennifer A. Westwood & Phillip K. Darcy. (2013) Gene-engineered T cells for cancer therapy. Nature Reviews Cancer 13:8, pages 525-541.
Crossref
Crossref
Hiroaki Asai, Hiroshi Fujiwara, Jun An, Toshiki Ochi, Yukihiro Miyazaki, Kozo Nagai, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Hirofumi Inoue & Masaki Yasukawa. (2013) Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor. PLoS ONE 8:2, pages e56820.
Crossref
Crossref
Agnieszka Wieczorek & Lutz Uharek. (2013) Genetically Modified T Cells for the Treatment of Malignant Disease. Transfusion Medicine and Hemotherapy 40:6, pages 388-402.
Crossref
Crossref
Katayoun Rezvani, Joshua D. Brody, Holbrook E. Kohrt, Aaron C. Logan, Ranjana Advani, Debra Katherine Czerwinski, Wen-Kai Weng, Robert S. Negrin, Victoria Carlton, Malek Faham, Ronald Levy & John Barrett. (2013) Cancer Vaccines and T Cell Therapy. Biology of Blood and Marrow Transplantation 19:1, pages S97-S101.
Crossref
Crossref
Ronnie Shapira-Frommer & Jacob Schachter. (2012) Adoptive Immunotherapy of Advanced Melanoma. Current Treatment Options in Oncology 13:3, pages 340-353.
Crossref
Crossref
Teresa FreireEduardo Osinaga. (2012) The sweet side of tumor immunotherapy. Immunotherapy 4:7, pages 719-734.
Crossref
Crossref
Benjamin J. Uttenthal, Ignatius Chua, Emma C. Morris & Hans J. Stauss. (2012) Challenges in T cell receptor gene therapy. The Journal of Gene Medicine 14:6, pages 386-399.
Crossref
Crossref
Pan Weibo & Ye Zhaoming. (2012) Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma. Medical Hypotheses 78:5, pages 616-618.
Crossref
Crossref
Tae Heung Kang, Chih-Ping Mao, Liangmei He, Ya-Chea Tsai, Katherine Liu, Victor La, T.-C. Wu & Chien-Fu Hung. (2012) Tumor-Targeted Delivery of IL-2 by NKG2D Leads to Accumulation of Antigen-Specific CD8+ T Cells in the Tumor Loci and Enhanced Anti-Tumor Effects. PLoS ONE 7:4, pages e35141.
Crossref
Crossref
Ronan J. Kelly, Elad Sharon, Ira Pastan & Raffit Hassan. (2012) Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. Molecular Cancer Therapeutics 11:3, pages 517-525.
Crossref
Crossref
Richard Wu, Marie-Andrée Forget, Jessica Chacon, Chantale Bernatchez, Cara Haymaker, Jie Qing Chen, Patrick Hwu & Laszlo G. Radvanyi. (2012) Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. The Cancer Journal 18:2, pages 160-175.
Crossref
Crossref
Gunter Rappl, Tobias Riet, Sabine Awerkiew, Annette Schmidt, Andreas A. Hombach, Herbert Pfister & Hinrich Abken. (2012) The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal Late-Stage T Cells. PLoS ONE 7:1, pages e30713.
Crossref
Crossref
Sivan Sapoznik, Ohad Hammer, Rona Ortenberg, Michal J. Besser, Tehila Ben-Moshe, Jacob Schachter & Gal Markel. (2012) Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms. Clinical and Developmental Immunology 2012, pages 1-9.
Crossref
Crossref
Markus Chmielewski, Caroline Kopecky, Andreas A. Hombach & Hinrich Abken. (2011) IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression. Cancer Research 71:17, pages 5697-5706.
Crossref
Crossref
Ettore Biagi, Virna Marin, Greta Attianese, Irene Pizzitola, Sarah Tettamanti, Elisabetta Cribioli & Andrea Biondi. (2011) New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future. Italian Journal of Pediatrics 37:1, pages 46.
Crossref
Crossref